Endologix, Inc. (NASDAQ:ELGX) – Research analysts at Piper Jaffray Companies increased their FY2019 earnings per share estimates for shares of Endologix in a report issued on Wednesday, November 6th, according to Zacks Investment Research. Piper Jaffray Companies analyst M. O’brien now forecasts that the medical instruments supplier will earn ($2.57) per share for the year, up from their prior forecast of ($2.69). Piper Jaffray Companies also issued estimates for Endologix’s Q4 2019 earnings at ($0.70) EPS, Q1 2020 earnings at ($0.47) EPS, Q2 2020 earnings at ($0.38) EPS, Q3 2020 earnings at ($0.42) EPS, Q4 2020 earnings at ($0.62) EPS, FY2020 earnings at ($1.89) EPS and FY2021 earnings at ($0.95) EPS.
A number of other equities analysts have also weighed in on the company. Zacks Investment Research lowered Endologix from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Royal Bank of Canada set a $7.00 target price on Endologix and gave the stock a “hold” rating in a research note on Friday, August 9th. Finally, ValuEngine lowered Endologix from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. Endologix presently has an average rating of “Hold” and a consensus price target of $7.17.
NASDAQ ELGX traded up $0.25 during trading on Monday, reaching $2.55. The company’s stock had a trading volume of 244,800 shares, compared to its average volume of 222,728. The stock has a market capitalization of $46.65 million, a PE ratio of -0.35 and a beta of 0.25. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.22 and a quick ratio of 1.55. The firm has a fifty day moving average of $3.03 and a 200 day moving average of $5.29. Endologix has a one year low of $2.28 and a one year high of $8.95.
Endologix (NASDAQ:ELGX) last announced its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.08. The business had revenue of $35.78 million for the quarter, compared to analyst estimates of $35.26 million. Endologix had a negative return on equity of 99.62% and a negative net margin of 58.24%.
Several institutional investors and hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC purchased a new position in shares of Endologix in the 2nd quarter worth about $17,828,000. Morgan Stanley boosted its holdings in Endologix by 1,395.2% during the 2nd quarter. Morgan Stanley now owns 722,419 shares of the medical instruments supplier’s stock valued at $5,230,000 after acquiring an additional 674,103 shares during the period. Vanguard Group Inc. boosted its holdings in Endologix by 32.6% during the 2nd quarter. Vanguard Group Inc. now owns 692,351 shares of the medical instruments supplier’s stock valued at $5,012,000 after acquiring an additional 170,316 shares during the period. Renaissance Technologies LLC boosted its holdings in Endologix by 868.3% during the 2nd quarter. Renaissance Technologies LLC now owns 613,906 shares of the medical instruments supplier’s stock valued at $4,445,000 after acquiring an additional 550,506 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its holdings in Endologix by 6.9% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 177,931 shares of the medical instruments supplier’s stock valued at $1,288,000 after acquiring an additional 11,497 shares during the period. Hedge funds and other institutional investors own 75.64% of the company’s stock.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Recommended Story: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.